Aliases & Classifications for Alopecia

MalaCards integrated aliases for Alopecia:

Name: Alopecia 39 12 77 30 6 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:987
ICD9CM 36 704.0 704.00
MeSH 45 D000505
NCIt 51 C50575
SNOMED-CT 69 56317004
ICD10 34 L65.9
UMLS 74 C0002170

Summaries for Alopecia

Disease Ontology : 12 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary : Alopecia is related to alopecia universalis congenita and clouston syndrome, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is HR (HR Lysine Demethylase And Nuclear Receptor Corepressor), and among its related pathways/superpathways are Adhesion and Cell adhesion_Endothelial cell contacts by junctional mechanisms. The drugs Clobetasol and Acitretin have been mentioned in the context of this disorder. Affiliated tissues include Hair and Hair, and related phenotypes are no effect and Mildly decreased CFP-tsO45G cell surface transport

Wikipedia : 77 Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 632)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 34.2 AIRE FOXN1 HR MBTPS2
2 clouston syndrome 32.2 ANTXR1 GJA1 TP63
3 nail disorder, nonsyndromic congenital, 1 31.9 AIRE MBTPS2 TP63
4 hypotrichosis 31.8 DCAF17 GJA1 HR KRT86
5 keratosis 30.2 DSP GJA1 MBTPS2
6 alopecia areata 12.7
7 alopecia, androgenetic, 1 12.6
8 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 12.5
9 androgenic alopecia 12.5
10 alopecia totalis 12.5
11 frontal fibrosing alopecia 12.5
12 central centrifugal cicatricial alopecia 12.4
13 mandibulofacial dysostosis with alopecia 12.4
14 palmoplantar keratoderma and congenital alopecia 2 12.4
15 alopecia, congenital 12.3
16 polyposis, skin pigmentation, alopecia, and fingernail changes 12.3
17 alopecia, epilepsy, pyorrhea, mental subnormality 12.3
18 diffuse alopecia areata 12.3
19 autosomal dominant palmoplantar keratoderma and congenital alopecia 12.3
20 alopecia, neurologic defects, and endocrinopathy syndrome 12.3
21 palmoplantar keratoderma and congenital alopecia 1 12.3
22 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.3
23 alopecia-contractures-dwarfism-intellectual disability syndrome 12.3
24 alopecia-contractures-dwarfism mental retardation syndrome 12.3
25 alopecia-mental retardation syndrome 1 12.3
26 autosomal recessive palmoplantar keratoderma and congenital alopecia 12.2
27 alopecia-intellectual disability syndrome 12.2
28 odonto onycho dysplasia with alopecia 12.2
29 alopecia areata 1 12.2
30 ichthyosis alopecia eclabion ectropion mental retardation 12.1
31 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 12.1
32 alopecia-mental retardation syndrome 2 12.1
33 alopecia-mental retardation syndrome 3 12.1
34 alopecia universalis onychodystrophy vitiligo 12.1
35 alopecia-epilepsy-oligophrenia syndrome of moynahan 12.0
36 woodhouse-sakati syndrome 12.0
37 alopecia universalis congenita, xy gonadal dysgenesis, and laryngomalacia 12.0
38 gapo syndrome 12.0
39 frontonasal dysplasia with alopecia and genital anomaly 12.0
40 lichen planopilaris 12.0
41 thumb deformity and alopecia 12.0
42 hypergonadotropic hypogonadism and partial alopecia 12.0
43 alopecia, androgenetic, 2 12.0
44 alopecia areata 2 12.0
45 alopecia, androgenetic, 3 12.0
46 alopecia intellectual disability syndrome 2 12.0
47 alopecia, familial focal 11.9
48 ichthyosis with alopecia, eclabium, ectropion, and mental retardation 11.9
49 alopecia-mental retardation syndrome with convulsions and hypergonadotropic hypogonadism 11.9
50 ectodermal dysplasia alopecia preaxial polydactyly 11.9

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 AHSG AIRE ANTXR1 AR AUTS2 CLDN1
2 Mildly decreased CFP-tsO45G cell surface transport GR00360-A-1 9.77 AHSG AIRE ANTXR1 AR DCAF17 DSP

MGI Mouse Phenotypes related to Alopecia:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.35 AHSG AIRE ANTXR1 AR AUTS2 CLDN1
2 cellular MP:0005384 10.33 ANTXR1 AR AUTS2 DCAF17 DSP EDNRA
3 cardiovascular system MP:0005385 10.3 ANTXR1 AR AUTS2 DSP EDNRA FOXN1
4 endocrine/exocrine gland MP:0005379 10.24 AIRE ANTXR1 AR AUTS2 EDNRA FOXN1
5 craniofacial MP:0005382 10.19 ANTXR1 AR DSP EDNRA GJA1 HR
6 mortality/aging MP:0010768 10.18 AIRE ANTXR1 AR AUTS2 CLDN1 DSP
7 digestive/alimentary MP:0005381 10.13 AIRE AR DSP EDNRA HR KRT14
8 immune system MP:0005387 10.13 AIRE ANTXR1 AR EDNRA FOXN1 GJA1
9 embryo MP:0005380 10.11 AR AUTS2 DSP EDNRA FOXN1 GJA1
10 integument MP:0010771 10.1 AR CLDN1 DSP EDNRA FOXN1 GJA1
11 hearing/vestibular/ear MP:0005377 10 AHSG EDNRA FOXN1 GJA1 HR KRT14
12 muscle MP:0005369 9.92 AHSG AR DSP EDNRA FOXN1 GJA1
13 neoplasm MP:0002006 9.86 AIRE ANTXR1 AR AUTS2 FOXN1 HR
14 reproductive system MP:0005389 9.85 AIRE ANTXR1 AR DCAF17 FOXN1 GJA1
15 skeleton MP:0005390 9.61 AHSG ANTXR1 AR EDNRA FOXN1 GJA1
16 vision/eye MP:0005391 9.23 AIRE EDNRA FOXN1 GJA1 HR HTRA1

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 524)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3 25122-46-7, 25122-41-2 32798 5311051
2
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
3
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 38304-91-5 4201
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
8
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
13
Abatacept Approved Phase 4,Phase 2 332348-12-6 10237
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
15
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
16
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5311221 5282380
17
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
18
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 99011-02-6 57469
19
Hydroxychloroquine Approved Phase 4 118-42-3 3652
20 Orange Approved Phase 4,Phase 1,Not Applicable
21
Capsaicin Approved Phase 4,Not Applicable 404-86-4 1548943
22
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 155206-00-1 5311027
23
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
24
Drospirenone Approved Phase 4 67392-87-4 68873
25
Aminolevulinic acid Approved Phase 4,Phase 3,Not Applicable 106-60-5 137
26
Tacrolimus Approved, Investigational Phase 4,Phase 1 104987-11-3 445643 439492 6473866
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
28
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 94-09-7, 1994-09-7 2337
30
tannic acid Approved Phase 4,Phase 3,Phase 2 1401-55-4
31
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 1 13422-55-4
32
Hydroxocobalamin Approved Phase 4,Phase 1 13422-51-0 11953898 15589840
33
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
34
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
35
Ketoconazole Approved, Investigational Phase 4,Phase 3 65277-42-1 47576
36
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 477600-75-2
37
Desogestrel Approved Phase 4 54024-22-5 40973
38
Levonorgestrel Approved, Investigational Phase 4,Phase 3 17489-40-6, 797-63-7 13109
39
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
40
Spironolactone Approved Phase 4,Phase 2 52-01-7, 1952-01-7 5833
41
Apremilast Approved, Investigational Phase 4,Phase 2,Not Applicable 608141-41-9 11561674
42
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
43
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
44
Warfarin Approved Phase 4 81-81-2 6691 54678486
45
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
47
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
48
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 1 68-19-9 44176380
49
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Not Applicable 2920-86-7
50
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 31703

Interventional clinical trials:

(show top 50) (show all 691)
# Name Status NCT ID Phase Drugs
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
2 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
3 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
5 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
6 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
7 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4 Aldara Cream 5%
8 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
9 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
10 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4 Capsaicin
11 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
12 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
13 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
14 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
15 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
16 The Vienna Prograf and Endothelial Progenitor Cell Study Completed NCT00182559 Phase 4 Ciclosporin;Tacrolimus
17 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
18 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4 pazopanib
19 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
20 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Recruiting NCT03800979 Phase 4 Tofacitinib
21 Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Recruiting NCT03422640 Phase 4 Apremilast
22 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
23 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
24 Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
25 Pain Outcomes Following Intralesional Corticosteroid Injections Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
26 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
27 Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant Active, not recruiting NCT03353012 Phase 4 Etonogestrel Drug Implant;Levonorgestrel Drug Implant
28 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
29 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
30 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
31 Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Not yet recruiting NCT03473600 Phase 4 Triamcinolone acetonide injection
32 DANWARD - Danish Warfarin-Dialysis Study Not yet recruiting NCT03862859 Phase 4 Warfarin
33 Pentoxifylline in Lupus Nephritis Not yet recruiting NCT03859570 Phase 4 Pentoxifylline;Placebos
34 Intralesional Steroids in the Treatment of Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
35 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
36 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
37 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
38 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
39 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
40 Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation Unknown status NCT01615757 Phase 3 Ara-c;Ara-c
41 Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Unknown status NCT01671384 Phase 3 Valproate, Levocarnitine;Placebo
42 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
43 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
44 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
45 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
46 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
47 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
48 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
49 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
50 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 30

Anatomical Context for Alopecia

MalaCards organs/tissues related to Alopecia:

42
Breast, Lung, Skin, Brain, T Cells, Prostate, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 4702)
# Title Authors Year
1
Types of hairline recession in androgenetic alopecia and perceptions of aging in Asian males. ( 30888056 )
2019
2
ALLERGIC CONTACT DERMATITIS PROBABLY DUE TO LATANOPROST DURING TREATMENT FOR ALOPECIA AREATA. ( 30663070 )
2019
3
Clinical Profile of Androgenic Alopecia and Its Association with Cardiovascular Risk Factors. ( 30745630 )
2019
4
The Association of Metabolic Syndrome and Insulin Resistance in Early-Onset Androgenetic Alopecia in Males: A Case-Control Study. ( 30745631 )
2019
5
Efficacy and Safety of Methotrexate in Combination with Mini Pulse Doses of Methylprednisolone in Severe Alopecia Areata. The Vietnamese Experience. ( 30745958 )
2019
6
The Effectiveness of Oral Mini-Pulse Methylprednisolonein - the Treatment of Alopecia Areata in Vietnam. ( 30745983 )
2019
7
Genetic analysis of a novel antioxidant multi-target iron chelator, M30 protecting against chemotherapy-induced alopecia in mice. ( 30760223 )
2019
8
Ischemic modified albumin as a new biomarker in predicting oxidative stress in alopecia areata ( 30762322 )
2019
9
JAK inhibitors for alopecia areata: a systematic review and meta-analysis. ( 30762909 )
2019
10
Variant PADI3 in Central Centrifugal Cicatricial Alopecia. ( 30763140 )
2019
11
Genetic Susceptibility to Alopecia. ( 30763143 )
2019
12
Alopecia neoplastica as a sign of visceral malignancies: a systematic review. ( 30767283 )
2019
13
Citalopram-Associated Alopecia: A Case Report and Brief Literature Review. ( 30767750 )
2019
14
Evaluation of Association of Vitamin D in Alopecia Areata: A Case-control Study of 100 Patients in a Tertiary Rural Hospital of Southern India. ( 30775298 )
2019
15
Alopecia and techniques in hair restoration: an overview for the cosmetic surgeon. ( 30788753 )
2019
16
Curvilinear Alopecia in an Infant. ( 30789026 )
2019
17
Differential expression patterns of specific long noncoding RNAs and competing endogenous RNA network in alopecia areata. ( 30790320 )
2019
18
The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review ( 30794366 )
2019
19
Frontal fibrosing alopecia: A new autoimmune entity? ( 30798907 )
2019
20
Reply reply to the comments on "The increasing incidence of frontal fibrosing alopecia. In search of triggering factors." ( 30803056 )
2019
21
Re: The increasing incidence of frontal fibrosing alopecia. In search of triggering factors. ( 30803064 )
2019
22
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial. ( 30806921 )
2019
23
Moth-eaten Alopecia in secondary syphilis. ( 30807867 )
2019
24
Resolution of pseudoainhum with acitretin therapy in a patient with palmoplantar keratoderma and congenital alopecia. ( 30809564 )
2019
25
Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. ( 30809579 )
2019
26
Association of Out-of-Pocket Health Care Costs and Financial Burden for Patients With Alopecia Areata. ( 30810706 )
2019
27
Axillary involvement in frontal fibrosing alopecia: clinical, dermoscopy and histological features. ( 30811648 )
2019
28
A Systematic Review of the Outcome of Hair Transplantation in Primary Scarring Alopecia. ( 30815438 )
2019
29
Complementary and Alternative Treatments for Alopecia: A Comprehensive Review. ( 30815439 )
2019
30
Frontal Fibrosing Alopecia: An Emerging Epidemic. ( 30815440 )
2019
31
Perinevoid Alopecia: A Case Report. ( 30815441 )
2019
32
A Case of Friction Alopecia in a Healthy 15-Year-Old Girl. ( 30815442 )
2019
33
Peripilar "Guttate" Hypopigmentation of the Scalp and Idiopathic Guttate Hypomelanosis in Frontal Fibrosing Alopecia. ( 30815443 )
2019
34
Serum Interleukin-15 is a Marker of Alopecia Areata Severity. ( 30820130 )
2019
35
Psoriatic alopecia-like paradoxical reaction to certolizumab pegol. ( 30825196 )
2019
36
Alopecia Areata After Treatment With Dupilumab. ( 30829800 )
2019
37
Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. ( 30830894 )
2019
38
Development of alopecia in patients treated with dupilumab. ( 30834653 )
2019
39
Finasteride for androgenetic alopecia is not associated with sexual dysfunction: A survey-based, single-center, controlled study. ( 30835851 )
2019
40
Minoxidil for Patchy Alopecia Areata: Systematic Review and Meta-Analysis. ( 30835901 )
2019
41
Amyloid-Associated Alopecia: A Reappraisal Including Its Pathophysiology. ( 30839340 )
2019
42
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. ( 30840033 )
2019
43
Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with low-level laser therapy. ( 30843235 )
2019
44
Use of trichoscopy for the diagnosis of alopecia areata coexisting with primary scarring alopecia in a female hair loss patient. ( 30843255 )
2019
45
Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02. ( 30850646 )
2019
46
Serum concentrations of selected proinflammatory cytokines in children with alopecia areata. ( 30858781 )
2019
47
Evaluation of selected parameters of oxidative stress in patients with alopecia areata. ( 30858790 )
2019
48
Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction. ( 30861165 )
2019
49
The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. ( 30863034 )
2019
50
Laser-assisted drug delivery for the treatment of androgenetic alopecia: ablative laser fractional photothermolysis to enhance cutaneous topical delivery of platelet-rich plasma - with or without concurrent bimatoprost and/or minoxidil. ( 30865404 )
2019

Variations for Alopecia

ClinVar genetic disease variations for Alopecia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SASH1 NM_015278.4(SASH1): c.1849G> A (p.Glu617Lys) single nucleotide variant Likely pathogenic rs587781245 GRCh38 Chromosome 6, 148533885: 148533885
2 SASH1 NM_015278.4(SASH1): c.1849G> A (p.Glu617Lys) single nucleotide variant Likely pathogenic rs587781245 GRCh37 Chromosome 6, 148855021: 148855021
3 EMILIN2; LPIN2; METTL4; MYL12A; MYL12B; MYOM1; NDC80; SMCHD1; TGIF1 GRCh37/hg19 18p11.32-11.31(chr18: 1345040-3479168) copy number loss Uncertain significance GRCh37 Chromosome 18, 1345040: 3479168

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

Pathways related to Alopecia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.22 CLDN1 DSP GJA1
2 10.3 CLDN1 DSP GJA1

GO Terms for Alopecia

Cellular components related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fascia adherens GO:0005916 8.96 DSP GJA1
2 intermediate filament GO:0005882 8.92 DSP GJA1 KRT14 KRT86

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 AIRE AR AUTS2 FOXN1 TP63 VDR
2 cell proliferation GO:0008283 9.81 AR EDNRA FOXN1 TP63
3 skeletal system development GO:0001501 9.7 AHSG TP63 VDR
4 animal organ morphogenesis GO:0009887 9.54 FOXN1 TP63 VDR
5 cornification GO:0070268 9.5 DSP KRT14 KRT86
6 cell-cell junction organization GO:0045216 9.49 CLDN1 GJA1
7 decidualization GO:0046697 9.46 GJA1 VDR
8 regulation of bone mineralization GO:0030500 9.43 AHSG GJA1
9 establishment of skin barrier GO:0061436 9.4 CLDN1 TP63
10 keratinocyte differentiation GO:0030216 9.33 DSP FOXN1 TP63
11 prostate gland development GO:0030850 9.26 AR TP63
12 epidermis development GO:0008544 9.26 DSP FOXN1 KRT14 TP63
13 thymus epithelium morphogenesis GO:0097536 8.62 AIRE FOXN1

Sources for Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....